Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity

John L, Kruse T, Raun K

Journal of the Endocrine Society3 May 2021

PMCIDPMC8089144PepBankPUB-90016701

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study18

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, concurrent AM833 plus semaglutide reduced body weight by 13.1%, more than either monotherapy.
In plain wordsIn rats, giving AM833 and semaglutide together caused more weight loss than either drug alone.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change in DIO rats, concurrent AM833 plus semaglutide
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Each monotherapy (semaglutide, AM833)
Outcome group
Body weight · Metabolic and weight
Studied dose
sub-maximal doses · subcutaneous · 24 or 28 daysAs given in this study (rat).
Measurements
Body weight change
−13.1%
concurrent combination, DIO rat
Source sentences
Summary
In the DIO rat, both concurrent (-13.1% ± 0.7%) and add-on (-12.8% ± 1.2%)
2 context sentences(design, population, supporting numbers)
Summary · context
treatment modes induced equivalent weight loss that was greater than each monotherapy (-6.3% ± 0.7%, 2 nmol/kg semaglutide and -5.8% ± 0.9%, 2 nmol/kg AM833) relative to initial body weights.
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Report a problemFND-9001670101
02AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, adding AM833 after one week of semaglutide reduced body weight by 12.8%, equivalent to concurrent dosing and more than either monotherapy.
In plain wordsIn rats, adding AM833 after a week of semaglutide caused as much weight loss as giving both together, and more than either alone.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change in DIO rats, add-on AM833 after semaglutide
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Each monotherapy (semaglutide, AM833)
Outcome group
Body weight · Metabolic and weight
Studied dose
sub-maximal doses · subcutaneous · 24 or 28 daysAs given in this study (rat).
Measurements
Body weight change
−12.8%
add-on combination, DIO rat
Source sentences
Summary
In the DIO rat, both concurrent (-13.1% ± 0.7%) and add-on (-12.8% ± 1.2%)
2 context sentences(design, population, supporting numbers)
Summary · context
treatment modes induced equivalent weight loss that was greater than each monotherapy (-6.3% ± 0.7%, 2 nmol/kg semaglutide and -5.8% ± 0.9%, 2 nmol/kg AM833) relative to initial body weights.
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Report a problemFND-9001670102
03AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, AM833 2 nmol/kg alone reduced body weight by 5.8% relative to initial body weight.
In plain wordsIn rats, AM833 alone caused a smaller weight loss than the combination with semaglutide.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change in DIO rats, AM833 alone
Study
ratn: not reported in source
Diet-induced obese rats
Outcome group
Body weight · Metabolic and weight
Studied dose
2 nmol/kg · subcutaneous · 24 or 28 daysAs given in this study (rat).
Measurements
Body weight change
−5.8%
AM833 2 nmol/kg, DIO rat
Source sentences
Summary
than each monotherapy (-6.3% ± 0.7%, 2 nmol/kg semaglutide and -5.8% ± 0.9%, 2 nmol/kg AM833) relative to initial body weights.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Report a problemFND-9001670103
04AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, concurrent AM833 plus semaglutide reduced body weight by 9.6%, more than either monotherapy.
In plain wordsIn mice, giving AM833 and semaglutide together caused more weight loss than either drug alone.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change in DIO mice, concurrent AM833 plus semaglutide
Study
mousen: not reported in source
Diet-induced obese mice
Comparator
Each monotherapy (semaglutide, AM833)
Outcome group
Body weight · Metabolic and weight
Studied dose
sub-maximal doses · subcutaneous · 24 or 28 daysAs given in this study (mouse).
Measurements
Body weight change
−9.6%
concurrent combination, DIO mouse
Source sentences
Summary
In the DIO mouse, weight loss in the combination groups was not significantly different (-9.6% ± 1.5%, concurrent vs. -11.5% ± 1.2%, add-on) but was greater than that observed in each monotherapy group (-1.9% ±1.2%, 1 nmol/kg semaglutide and +1.5% ± 2.2%, 10 nmol/kg AM833).
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Report a problemFND-9001670106
05AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, adding AM833 after semaglutide reduced body weight by 11.5%, not significantly different from concurrent dosing and more than either monotherapy.
In plain wordsIn mice, adding AM833 after semaglutide caused weight loss similar to giving both together, and more than either drug alone.
Peptide
Cagrilintide
Outcome
DecreaseBody weight change in DIO mice, add-on AM833 after semaglutide
Study
mousen: not reported in source
Diet-induced obese mice
Comparator
Each monotherapy (semaglutide, AM833)
Outcome group
Body weight · Metabolic and weight
Studied dose
sub-maximal doses · subcutaneous · 24 or 28 daysAs given in this study (mouse).
Measurements
Body weight change
−11.5%
add-on combination, DIO mouse
Source sentences
Summary
In the DIO mouse, weight loss in the combination groups was not significantly different (-9.6% ± 1.5%, concurrent vs. -11.5% ± 1.2%, add-on) but was greater than that observed in each monotherapy group (-1.9% ±1.2%, 1 nmol/kg semaglutide and +1.5% ± 2.2%, 10 nmol/kg AM833).
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Report a problemFND-9001670107
06AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, AM833 10 nmol/kg alone did not reduce body weight (+1.5%); significance is not stated.
In plain wordsIn mice, AM833 alone at this dose did not cause weight loss.
Peptide
Cagrilintide
Outcome
Direction not reportedBody weight change in DIO mice, AM833 alone
Study
mousen: not reported in source
Diet-induced obese mice
Outcome group
Body weight · Metabolic and weight
Studied dose
10 nmol/kg · subcutaneous · 24 or 28 daysAs given in this study (mouse).
Measurements
Body weight change
1.5%
AM833 10 nmol/kg, DIO mouse
Source sentences
Summary
but was greater than that observed in each monotherapy group (-1.9% ±1.2%, 1 nmol/kg semaglutide and +1.5% ± 2.2%, 10 nmol/kg AM833).
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Report a problemFND-9001670108
07AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, semaglutide alone at 2 nmol/kg once daily reduced body weight by 6.3% relative to initial body weight.
In plain wordsIn obese rats, semaglutide alone lowered body weight by about 6.3% compared with the starting weight.
Peptide
Semaglutide
Outcome
DecreaseBody weight change with semaglutide alone in DIO rats
Study
ratn: not reported in source
Diet-induced obese (DIO) rat
Comparator
Initial body weight
Outcome group
Body weight · Metabolic and weight
Studied dose
2 nmol/kg once daily · subcutaneous · 24 or 28 daysAs given in this study (rat).
Measurements
Body weight change
−6.3%
semaglutide 2 nmol/kg, DIO rat
Source sentences
Summary
each monotherapy (-6.3% ± 0.7%, 2 nmol/kg semaglutide
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Report a problemFND-9001670110
08AnimalAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, semaglutide alone at 1 nmol/kg once daily changed body weight by -1.9% relative to initial body weight.
In plain wordsIn obese mice, semaglutide alone lowered body weight by about 1.9% compared with the starting weight.
Peptide
Semaglutide
Outcome
DecreaseBody weight change with semaglutide alone in DIO mice
Study
mousen: not reported in source
Diet-induced obese (DIO) mouse
Comparator
Initial body weight
Outcome group
Body weight · Metabolic and weight
Studied dose
1 nmol/kg once daily · subcutaneous · 24 or 28 daysAs given in this study (mouse).
Measurements
Body weight change
−1.9%
semaglutide 1 nmol/kg, DIO mouse
Source sentences
Summary
each monotherapy group (-1.9% ±1.2%, 1 nmol/kg semaglutide
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
Report a problemFND-9001670111

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

09AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, both combination groups reached the body weight of lean age-matched control rats.
In plain wordsIn rats, both combination treatments brought body weight down to the level of lean rats.
Peptide
Cagrilintide
Outcome
DecreaseBody weight normalization in DIO rats
Study
ratn: not reported in source
Diet-induced obese rats
Comparator
Lean age-matched control rats
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Both combination groups achieved normalization of body weight to that of lean age-matched control rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-9001670104
10AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, reductions in cumulative food intake corresponded with the extent of weight loss.
In plain wordsIn rats, treatment lowered food intake, and the drop matched the amount of weight lost.
Peptide
Cagrilintide
Outcome
DecreaseCumulative food intake in DIO rats
Study
ratn: not reported in source
Diet-induced obese rats
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Reductions in cumulative food intake corresponded with the extent of weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-9001670105
11AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, body weight did not normalize to that of lean controls with combination treatment.
In plain wordsIn mice, the combination did not bring body weight down to the level of lean mice.
Peptide
Cagrilintide
Outcome
No significant changeBody weight normalization in DIO mice
Study
mousen: not reported in source
Diet-induced obese mice
Comparator
Lean control mice
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
In the DIO mouse, body weight did not normalize to match that of lean controls with combination treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-9001670109
12AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, concurrent dosing of AM833 and semaglutide reduced body weight by 13.1%, more than each monotherapy.
In plain wordsIn obese rats, giving AM833 and semaglutide together lowered body weight more than either drug alone.
Peptide
Semaglutide
Outcome
DecreaseBody weight change with concurrent AM833 plus semaglutide in DIO rats
Study
ratn: not reported in source
Diet-induced obese (DIO) rat
Comparator
Each monotherapy
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−13.1%
concurrent AM833 plus semaglutide, DIO rat
Source sentences
Summary
In the DIO rat, both concurrent (-13.1% ± 0.7%) and add-on (-12.8% ± 1.2%) treatment modes induced equivalent weight loss that was greater than each monotherapy (-6.3% ± 0.7%, 2 nmol/kg semaglutide and -5.8% ± 0.9%, 2 nmol/kg AM833) relative to initial body weights.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-9001670112
13AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, adding AM833 after one week of semaglutide reduced body weight by 12.8%, more than each monotherapy.
In plain wordsIn obese rats, adding AM833 to semaglutide lowered body weight more than either drug alone.
Peptide
Semaglutide
Outcome
DecreaseBody weight change with add-on AM833 after semaglutide in DIO rats
Study
ratn: not reported in source
Diet-induced obese (DIO) rat
Comparator
Each monotherapy
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−12.8%
add-on AM833 after semaglutide, DIO rat
Source sentences
Summary
In the DIO rat, both concurrent (-13.1% ± 0.7%) and add-on (-12.8% ± 1.2%) treatment modes induced equivalent weight loss that was greater than each monotherapy (-6.3% ± 0.7%, 2 nmol/kg semaglutide and -5.8% ± 0.9%, 2 nmol/kg AM833) relative to initial body weights.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-9001670113
14AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, both combination modes of AM833 and semaglutide brought body weight to the level of lean age-matched control rats.
In plain wordsIn obese rats, AM833 plus semaglutide brought body weight down to the level of lean rats.
Peptide
Semaglutide
Outcome
DecreaseNormalisation of body weight to lean controls with AM833 plus semaglutide in DIO rats
Study
ratn: not reported in source
Diet-induced obese (DIO) rat
Comparator
Lean age-matched control rats
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Both combination groups achieved normalization of body weight to that of lean age-matched control rats.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-9001670114
15AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese rats, cumulative food intake fell in line with the weight loss of the AM833 plus semaglutide treatments.
In plain wordsIn obese rats, eating less matched the weight loss seen with AM833 plus semaglutide.
Peptide
Semaglutide
Outcome
DecreaseCumulative food intake with AM833 plus semaglutide in DIO rats
Study
ratn: not reported in source
Diet-induced obese (DIO) rat
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Reductions in cumulative food intake corresponded with the extent of weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-9001670115
16AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, concurrent dosing of AM833 and semaglutide reduced body weight by 9.6%, more than each monotherapy.
In plain wordsIn obese mice, giving AM833 and semaglutide together lowered body weight more than either drug alone.
Peptide
Semaglutide
Outcome
DecreaseBody weight change with concurrent AM833 plus semaglutide in DIO mice
Study
mousen: not reported in source
Diet-induced obese (DIO) mouse
Comparator
Each monotherapy
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−9.6%
concurrent AM833 plus semaglutide, DIO mouse
Source sentences
Summary
In the DIO mouse, weight loss in the combination groups was not significantly different (-9.6% ± 1.5%, concurrent vs. -11.5% ± 1.2%, add-on) but was greater than that observed in each monotherapy group (-1.9% ±1.2%, 1 nmol/kg semaglutide and +1.5% ± 2.2%, 10 nmol/kg AM833).
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-9001670116
17AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, adding AM833 after semaglutide reduced body weight by 11.5%, more than each monotherapy.
In plain wordsIn obese mice, adding AM833 to semaglutide lowered body weight more than either drug alone.
Peptide
Semaglutide
Outcome
DecreaseBody weight change with add-on AM833 after semaglutide in DIO mice
Study
mousen: not reported in source
Diet-induced obese (DIO) mouse
Comparator
Each monotherapy
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−11.5%
add-on AM833 after semaglutide, DIO mouse
Source sentences
Summary
In the DIO mouse, weight loss in the combination groups was not significantly different (-9.6% ± 1.5%, concurrent vs. -11.5% ± 1.2%, add-on) but was greater than that observed in each monotherapy group (-1.9% ±1.2%, 1 nmol/kg semaglutide and +1.5% ± 2.2%, 10 nmol/kg AM833).
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-9001670117
18AnimalNot a test of Semaglutide aloneAnimal study (in vivo)Efficacy outcome
In diet-induced obese mice, body weight did not normalise to the level of lean controls with AM833 plus semaglutide.
In plain wordsIn obese mice, AM833 plus semaglutide did not bring body weight down to the level of lean mice.
Peptide
Semaglutide
Outcome
No significant changeNormalisation of body weight to lean controls with AM833 plus semaglutide in DIO mice
Study
mousen: not reported in source
Diet-induced obese (DIO) mouse
Comparator
Lean control mice
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
In the DIO mouse, body weight did not normalize to match that of lean controls with combination treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Diet-induced obese (DIO) rats and mice on a high energy diet were dosed subcutaneously once-daily for 24 or 28 days with sub-maximal doses of AM833, semaglutide or two modes of combination treatments.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-9001670118

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.